Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Cephalon
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Documented B-Cell NHL or mantle cell lymphoma
CD-20+ tumor
Indolent NHL: follicular B-cell lymphoma, diffuse small lymphoma, marginal zone lymphoma
Maximum of three prior chemotherapy regimens
Age of at least 18 years at Screening Visit (Site specific requirement may differ)
You may not be if
Refractory to rituximab, defined as progression of disease while being treated with rituximab or progression within 6 months of the last dose of rituximab (when given either as a single agent or in combination)
Previous chemotherapy or immunotherapy within 3 weeks prior to entering the study (6 weeks for nitrosoureas or mitomycin) or failure to recover from adverse events due to any agents administered previously
Use of investigational agents within 28 days of study
History of prior high dose chemotherapy with allogeneic stem cell support
History of prior radioimmunotherapy
Clareo Health | SDX-105 in Combination With Rituxan for Patients With Relapsed Indolent or Mantle Cell Non-Hodgkin's Lymphoma (NHL)
